Phase II trial

Non-small cell lung cancer
#Candel Therapeutics #Immunotherapy #Lung cancer #Oncology #Phase II trial

Unique immunotherapy extends survival in advanced NSCLC

Candel Therapeutics’ CAN-2409 has demonstrated a median overall survival (mOS) of 24.5 months in a Phase IIa clinical trial in patients with stage III/IV non-small cell lung cancer (NSCLC).  The 46 evaluable patients, who are nonresponsive to immune checkpoint inhibitor (ICI) treatment, received two courses of CAN-2409. Read More

#Cancer Research #Editor's Choice #News

Respiratory syncytial virus
#ENA Respiratory #Immunology / Virology & Vaccines #Phase II trial #Respiratory #University of Maryland

Vaccine centre hosts study of antiviral host defence enhancer

ENA Respiratory and the University of Maryland have announced plans to partner on a Phase II study of INNA-051 for the prevention of illness due to viral respiratory infections.  Dr Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine’s Center for Vaccine and… Read More

#News

Alpha-synuclein protein aggregate
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #Phase II trial

Immunotherapy for Parkinson’s induces positive responses

AC Immune has announced additional interim safety and positive immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056, its anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease (PD).  Dr Andrea Pfeifer, CEO of AC Immune, commented: “We continue to be encouraged by the data… Read More

#News

DNA vector
#Gene editing #Gene therapy #iECURE #Phase II trial

Study indicates gene editing could restore OTC enzyme activity

Gene editing company iECURE has shared data from the ongoing OTC-HOPE Phase I/II study of ECUR-506, which suggest partial restoration of functional ornithine transcarbamylase (OTC) enzyme activity in the first patient dosed.  “Long-term restoration of ornithine transcarbamylase activity has the potential to allow infants afflicted with neonatal… Read More

#News #Trending News

Polio virus attached motor neurone
#Grifols #Phase II trial #Polio #University of Amsterdam

Trial supports immunoglobulin in post-polio patients

Positive results from a Phase II/III clinical trial evaluating Grifols’ intravenous immunoglobulin (IVIG) to treat patients with post-polio syndrome (PPS) have demonstrated a significant improvement in distance walked compared to placebo.  The immunomodulatory properties of IVIG – in this case Flebogamma 5% DIF (immune globulin intravenous [human])… Read More

#News

Cancer cells
#Japan #Oncology #Phase II trial #Rare cancers

Dual approach could transform treatment of rare cancer

Researchers have combined immunotherapy and chemotherapy to offer new hope for patients with thymic carcinoma, a rare and aggressive cancer.  Thymic carcinoma is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy.   Now, researchers… Read More

#Cancer Research #News #Trending News

Monoclonal antibodies
#Inflammatory Bowel Disease #Monoclonal antibodies #Phase II trial #Sanofi #Teva

New data indicate duvakitug could “transform” IBD treatment

Sanofi and Teva Pharmaceuticals have revealed new results from their Phase IIb study of duvakitug for ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease (IBD).   The results were shared in two oral presentations at the 20th Congress of the… Read More

#News #Trending News

Child with cystic fibrosis on ventilator
#Boehringer Ingelheim #Cystic fibrosis #Gene therapy #Imperial College London #Phase II trial

Inhaled gene therapy for cystic fibrosis enters the clinic

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and OXB have announced the start of LENTICLAIR 1, a Phase I/II trial of gene therapy BI 3720931.  The therapy has been designed to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene… Read More

#News

#Genetic diseases #Grifols #Lung disease #Phase II trial

Trials advance subcutaneous plasma therapy for AAT deficiency 

Grifols has finished recruiting the second cohort of its Phase I/II study evaluating two different doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%) as a subcutaneous (SC) option for the treatment of alpha1-antitrypsin (AAT) deficiency.  Cohort 2 patients will receive a 180mg/kg dose of SC Alpha-1… Read More

#News

Gene therapy
#Asklepios BioPharmaceutical #Gene therapy #Heart failure #Phase II trial

First European participant in heart failure gene therapy trial

AskBio announced that the first participant has been randomised in Europe in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II clinical trial of AB-1002 for the treatment of congestive heart failure (CHF).  GenePHIT is an adaptive, double-blind, placebo-controlled, randomised, multicentre trial to evaluate the… Read More

#News

Fibrosis lungs
#Avalyn Pharma #Deep learning #Fibrosis #Phase II trial #Qureight

Deep learning to provide insights in pulmonary fibrosis trial 

Qureight and Avalyn Pharma have announced the initiation of a strategic partnership in progressive pulmonary fibrosis, commencing with the ongoing MIST study.  The MIST study is a Phase IIb clinical trial evaluating the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Read More

#News

Telomeres on chromosomes
#DNA #Lung cancer #MAIA Biotechnology #Oncology #Phase II trial

Positive efficacy updates for Phase II trial in non-small cell lung cancer

MAIA Biotechnology has shared positive updated data from its THIO-101 Phase II clinical trial evaluating its lead candidate, THIO, in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.  In the trial, THIO was sequenced with Regeneron’s immune checkpoint inhibitor… Read More

#Cancer Research #News

Mosquito
#Immunology / Virology & Vaccines #Monoclonal antibodies #National Institutes of Health (NIH) #Phase II trial

Phase II trial will test monoclonal antibody for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment for the effects of dengue, a mosquito-borne viral disease.   The study is supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).  It will test the ability of… Read More

#News

Soft tissue sarcoma
#Oncology #Phase II trial #Sarcoma #Vyome Therapeutics

Topical gel could be a breakthrough in cancer wounds

Vyome Therapeutics has shared interim results from its Phase II proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (MFW).  VT-1953, which exerts an immuno-anti-inflammatory effect by targeting TLR-MD2 and DNA gyrase, met its primary endpoint in this interim analysis, with patients… Read More

#Cancer Research #News

Close up of vaccine syringe
#Cancer vaccine #HPV #Immunology / Virology & Vaccines #Oncology #Phase II trial #Women's health

Therapeutic HPV vaccine could eliminate precancerous cervical lesions

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).  Dr Refika Yigit, principal investigator and Oncological Gynaecologist at University… Read More

#Cancer Research #News

Two scientists working in a research laboratory
#Cancer Research UK #Oncology #Peptides #Phase II trial #Rare cancers

UK-Norwegian collaboration to trial peptide for rare cancer

Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase II clinical trial for patients with adrenocortical carcinoma (ACC).  CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer… Read More

#Business & Investment #Cancer Research #News